Method for preparing cells for treating disease, method for promoting migration ability of cells, method for promoting proliferation ability of cells, and cells obtained by these methods
By sonicating mesenchymal stem cells at a frequency of 30 kHz to 2.0 MHz, the problem of insufficient migration and proliferation ability is solved, and the accumulation ability and therapeutic effect in inflammatory tissues or tumor tissues is significantly improved.
Patent Information
- Application Number
- CN202380019469.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-02-03
- Filing Date
- 2023-01-26
- Publication Date
- 2024-11-05
AI Technical Summary
The prior art is difficult to effectively enhance the migration and proliferation ability of mesenchymal stem cells, limiting their therapeutic effect in treating diseases.
By sonicating mesenchymal stem cells, especially in the frequency range of 30 kHz to 2.0 MHz, their migration and proliferation ability can be enhanced, thereby accumulating more cells in inflammatory tissues or tumor tissues, improving the therapeutic effect.
Through ultrasound treatment, the migration and proliferation ability of mesenchymal stem cells is significantly improved, which can accumulate a large number of cells in the disease site, enhancing the therapeutic effect on inflammatory tissues or tumors.
Smart Images

Figure HDA0004969812860000011 
Figure HDA0004969812860000012 
Figure HDA0004969812860000021
Abstract
Description
Technical Field
[0001] The present invention relates to a method for preparing cells for treating diseases, a method for promoting the migration ability of cells, a method for promoting the proliferation ability of cells, and cells obtained by these methods. Background Art
[0002] Mesenchymal stem cell (MSC) is a pluripotent progenitor cell, which was first separated from bone marrow by Friedenstein in 1982 (referring to non-patent literature 1). It has been shown that mesenchymal stem cells are present in various tissues such as bone marrow, umbilical cord and fat, and mesenchymal stem cell transplantation is expected to be a new treatment method for various refractory diseases (referring to non-patent literature 1 and 2). Recently, it is known that cells with similar functions are present in the stromal cells of adipose tissue, placenta, umbilical cord or egg membranes etc. Therefore, mesenchymal stem cells are sometimes referred to as mesenchymal stromal cells.
[0003] As is well known, mesenchymal stem cells are used for regenerative medicine etc. because they have tissue repair effect and immunosuppressive effect. However, the mechanism that mesenchymal stem cells play such effects has not been fully elucidated. Recently, it has been reported that mesenchymal stem cells have the characteristics of active accumulation in inflammatory tissue or tumor tissue in vivo, and it is believed that mesenchymal stem cells can secrete cytokines or exosomes etc. in inflammatory tissue or tumor tissue in vivo to act on surrounding cells, thereby promoting the repair of inflammatory tissue. (Non-patent literature 3 and 4). In such cases, there is a demand for the technology for further enhancing the therapeutic effect of mesenchymal stem cells.
[0004] Citation List
[0005] Non-patent literature
[0006] NPL 1: Pittenger FM et al. Science, (1999), 284, pp. 143-147
[0007] PTL 2: Cell Transplantation,(2016),25,pp.829-848
[0008] PTL 3: iScience,(2019)15,pp.421-438
[0009] PTL 4: Int J Med Sci.(2018),15(10),pp.1051-1061 Summary of the invention
[0010] Problem that the invention aims to solve
[0011] Under the above circumstances, an object of the present invention is to provide a method for obtaining cells having high migration ability or cells having high proliferation ability as cells having a further enhanced therapeutic effect on a disease.
[0012] Solutions for solving problems
[0013] The inventor believes that increasing the accumulation of cells in inflammatory tissue or tumor tissue leads to a further enhanced therapeutic effect of cells, and in order to solve the above problem, in-depth research has been carried out. Therefore, the inventor finds that the ultrasonic treatment of mesenchymal stem (matrix) cells (MSC) is effective in enhancing the migration ability and proliferation ability of mesenchymal stem (matrix) cells, and has completed the present invention. According to the present invention, cells with high migration ability and cells with high proliferation ability can be provided. That is, the invention content of the present invention is as follows.
[0014] [1] A method for preparing cells for treating a disease, the method comprising subjecting the cells to ultrasonic treatment.
[0015] [2] The method for preparing cells for treating a disease according to [1], wherein the frequency of the ultrasonic treatment is 30 kHz to 2.0 MHz.
[0016] [3] The method for preparing cells for treating a disease according to [1] or [2], wherein the cells are mesenchymal stem cells.
[0017] [4] A method for promoting the migration ability of cells, the method comprising subjecting the cells to ultrasonic treatment.
[0018] [5] The method for promoting cell migration according to [4], wherein the frequency of ultrasonic treatment is 30 kHz to 2.0 MHz.
[0019] [6] The method for promoting the migration ability of cells according to [4] or [5], wherein the cells are mesenchymal stem cells.
[0020] [7] A method for promoting the proliferation ability of cells, the method comprising subjecting the cells to ultrasonic treatment.
[0021] [8] The method for promoting cell proliferation according to [7], wherein the frequency of ultrasonic treatment is 30 kHz to 2.0 MHz.
[0022] [9] The method for promoting the migration ability of cells according to [7] or [8], wherein the cells are mesenchymal stem cells.
[0023]
[10] Cells were treated with ultrasound at a frequency of 30 kHz to 2.0 MHz.
[0024]
[11] mesenchymal stem cells treated with ultrasound at a frequency of 30 kHz to 2.0 MHz.
[0025] Effects of the Invention
[0026] According to the present invention, a novel method for promoting the migration ability of cells and cells having the migration ability promoted thereby can be provided. In addition, according to the present invention, a novel method for promoting the proliferation ability of cells and cells having the proliferation ability promoted thereby can be provided. According to the present invention, cells with excellent migration ability and cells with excellent proliferation ability can be obtained, and therefore it is believed that a large number of cells can be accumulated in disease sites such as inflammatory tissues or tumor tissues, and the therapeutic effect of cells on diseases can be enhanced. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] [ Figure 1 ] Figure 1 It is a graph showing the cell proliferation ability of mesenchymal stem cells.
[0028] [ Figure 2 ] Figure 2 It is a graph showing the cell proliferation ability of mesenchymal stem cells.
[0029] [ Figure 3 ] Figure 3 It is a graph showing the cell proliferation ability of mesenchymal stem cells.
[0030] [ Figure 4 ] Figure 4 It is a graph showing the cell proliferation ability of mesenchymal stem cells.
[0031] [ Figure 5 ] Figure 5 It is a graph showing the cell proliferation ability of mesenchymal stem cells.
[0032] [ Figure 6 ] Figure 6 Shows the results of the scratch test.
[0033] [ Figure 7 ] Figure 7 It is a graph showing the quantification of the results of the scratch test.
[0034] [ Figure 8 ] Figure 8 Shows staining of cells that migrated to the lower surface of the Transwell in the migration capacity assay.
[0035] [ Fig. 9 ] Fig. 9 Shown is the number of cells that migrated to the lower surface of the Transwell in the migration ability assay.
[0036] [ Fig.10 ] Fig.10Shows staining of cells that migrated to the lower surface of the Transwell in the migration capacity assay.
[0037] [ Fig.11 ] Fig.11 Shown is the number of cells that migrated to the lower surface of the Transwell in the migration ability assay.
[0038] [ Fig.12 ] Fig.12 Showing the results of time-dependent repair in a scratch test.
[0039] [ Fig.13 ] Fig.13 It is a graph showing the quantitative repair rate (%) after 9 hours in the scratch test.
[0040] [ Fig.14 ] Fig.14 Shows staining of cells that migrated to the lower surface of the Transwell in the migration capacity assay.
[0041] [ Fig.15 ] Fig.15 Shown is the number of cells that migrated to the lower surface of the Transwell in the migration ability assay.
[0042] [ Fig.16 ] Fig.16 Showing the results of time-dependent repair in a scratch test.
[0043] [ Fig.17 ] Fig.17 It is a graph showing the quantitative repair rate (%) after 9 hours in the scratch test. DETAILED DESCRIPTION
[0044] Hereinafter, a method for preparing cells for treating diseases, a method for promoting the migration ability of cells, a method for promoting the proliferation ability of cells, and cells obtained by these methods according to the present invention will be described in detail.
[0045] <Method for preparing cells for treating diseases>
[0046] The method for preparing cells for treating diseases according to the present invention is characterized in that the cells are subjected to ultrasonic treatment. According to the present invention, by subjecting cells to ultrasonic treatment under specific conditions, the migration ability of the cells can be enhanced, and cells with high accumulation in disease sites such as inflammatory tissues or tumor tissues can be provided, so that the therapeutic effect on the disease can be further enhanced. Hereinafter, the method for preparing cells for treating diseases according to the present invention will be described.
[0047] (cell)
[0048] The cells in the present invention are not particularly limited as long as they are cells that play a role in the treatment of the disease, and examples thereof include mesenchymal stem cells, placenta-derived stem cells, cord blood-derived cells, peripheral blood mononuclear cells (including neutrophils, eosinophils, basophils, lymphocytes and monocytes, etc.), erythrocytes, T cells, NK cells, NKT cells, NKM cells, LAK cells, dendritic cells, fibroblasts, hematopoietic stem cells, iPS cells, ES cells, bone marrow cells, cardiomyocytes, hepatocytes, nerve cells, dermal cells, adipocytes, and other cells constituting each tissue. Among them, from the viewpoint of further improving migration ability by ultrasonic treatment and exerting excellent effects on disease treatment, mesenchymal stem cells, placenta-derived stem cells, cord blood-derived cells, peripheral blood mononuclear cells, and bone marrow cells are preferred, and mesenchymal stem cells are more preferred.
[0049] In the present invention, mesenchymal stem cells refer to cells with the effect of differentiating into more than one type of cells (osteocytes, cardiomyocytes, chondrocytes, tendon cells or adipocytes, etc.) belonging to the mesenchymal system, and can proliferate while maintaining such effect. The term mesenchymal stem cells used in the present invention refers to the same cells as mesenchymal stromal cells, and there is no special difference between the two. In addition, mesenchymal stem cells are sometimes also referred to as mesenchymal cells. Examples of tissues comprising mesenchymal stem cells include adipose tissue, umbilical cord, bone marrow, cord blood, endometrium, placenta, amnion, chorion, decidua, dermis, skeletal muscle, periosteum, dental follicle, periodontal ligament, dental pulp and tooth germ. For example, adipose tissue-derived mesenchymal stem cells refer to mesenchymal stem cells contained in adipose tissue, and may also be referred to as adipose tissue-derived mesenchymal stromal cells. Among them, from the viewpoint of effectiveness in treating diseases or from the viewpoint of availability, etc., adipose tissue-derived mesenchymal stem cells, umbilical cord-derived mesenchymal stem cells, bone marrow-derived mesenchymal stem cells, placenta-derived mesenchymal stem cells, and dental pulp-derived mesenchymal stem cells are preferred, adipose tissue-derived mesenchymal stem cells and umbilical cord-derived mesenchymal stem cells are more preferred, and adipose-derived mesenchymal stem cells are most preferred.
[0050] The mesenchymal stem cells in the present invention can be cells provided by, for example, PromoCell GmbH, Lonza Group AG, Biological Industries, Veritas Corporation, R&D Systems, Inc. or Corning Incorporated, or can be cells prepared by methods well known to those skilled in the art. In addition, the mesenchymal stem cells can be primary cells isolated from donor tissues, or can be cells of established cell lines.
[0051] As a preparation method well known to those skilled in the art, for example, the mesenchymal stem cells of the present invention can be prepared by obtaining cells from each tissue by enzymatic digestion or physical cutting, then settling the cells, resuspending the cells in an appropriate culture medium, and culturing the cells. In addition, examples of methods for culturing cells include, but are not limited to, methods for culturing cells on a solid surface such as a culture dish or flask, methods for agitating and culturing spherical cell clusters by agglomerating cells, and methods for culturing cells by stirring cells adhered to microcarriers.
[0052] Examples of species of the mesenchymal stem cells in the present invention include humans, horses, cattle, sheep, pigs, dogs, cats, rabbits, mice, and rats.
[0053] In the present invention, mesenchymal stem cells of tissue origin such as adipose tissue-derived mesenchymal stem cells, umbilical cord-derived mesenchymal stem cells, or bone marrow-derived mesenchymal stem cells refer to any cell populations including mesenchymal stem cells of tissue origin such as adipose tissue-derived mesenchymal stem cells, umbilical cord-derived mesenchymal stem cells, or bone marrow-derived mesenchymal stem cells, respectively. At least 20%, preferably 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 93%, 96%, 97%, 98%, or 99% of the cell population is composed of mesenchymal stem cells of tissue origin such as adipose tissue-derived mesenchymal stem cells, umbilical cord-derived mesenchymal stem cells, or bone marrow-derived mesenchymal stem cells.
[0054] The culture medium for culturing cells of the present invention is not particularly limited, as long as it is a culture medium that can culture mesenchymal stem cells, and such culture medium can be prepared by supplementing the basal culture medium with serum, and / or with one or more serum substitutes such as albumin, transferrin, fatty acids, insulin, sodium selenite, cholesterol, collagen precursors, trace elements, 2-mercaptoethanol, or 3'-thioglycerol. Such culture medium can be further supplemented with substances such as lipids, amino acids, proteins, polysaccharides, vitamins, growth factors, low molecular weight compounds, antibiotics, antioxidants, pyruvic acid, buffers, or inorganic salts as needed.
[0055] Examples of the basal medium include IMDM medium, Medium 199 medium, Eagle's Minimum Essential Medium (EMEM) medium, MEM-α medium, Dulbecco's modified Eagle's Medium (DMEM) medium, Ham's F12 medium, RPMI1640 medium, Fischer's medium, MCDB201 medium, and mixed medium thereof.
[0056] Examples of serum include, but are not limited to, human serum, fetal bovine serum (FBS), bovine serum, calf serum, goat serum, horse serum, pig serum, sheep serum, rabbit serum, and rat serum, etc. When serum is used, the basal medium can be supplemented with it in an amount of 5 v / v% to 15 v / v%, preferably 10 v / v%.
[0057] The mesenchymal stem cells in the present invention may be appropriately cells that have been subjected to repeated cryopreservation and thawing. In the present invention, cryopreservation may be performed by suspending the mesenchymal stem cells in a cryopreservation solution well known to those skilled in the art and cooling them. The thawed mesenchymal stem cells may be appropriately cultured before the next cryopreservation. The culture of mesenchymal stem cells is performed using the above-mentioned culture medium capable of culturing mesenchymal stem cells, and is not particularly limited.
[0058] The mesenchymal stem cells in the present invention can be prepared as described above, and can be defined as cells having the following characteristics;
[0059] (1) They show adhesion to plastic under culture conditions in standard culture medium,
[0060] (2) they are positive for surface antigens CD44, CD73, and CD90, and negative for CD31, CD34, and CD45, and
[0061] (3) Under culture conditions, they can differentiate into osteocytes, adipocytes, or chondrocytes.
[0062] The mesenchymal stem cells of the present invention can be used for various diseases, and specific diseases include GVHD, chondrolysis, rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, spondyloarthritis, osteoarthritis, gout, psoriasis, multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, congestive heart failure, stroke, aortic valve stenosis, renal failure, nephrotic syndrome, uremia, lupus, pancreatitis, allergy, fibrosis, anemia, atherosclerosis, restenosis, chemotherapy / radiotherapy related complications, type I diabetes, type II diabetes, liver failure, autoimmune hepatitis, hepatitis C, primary biliary cirrhosis, primary sclerosing cholangitis, fulminant liver inflammation, celiac disease, nonspecific colitis, intestinal lymphangiectasia, protein-losing enteropathy, Crohn's disease, allergic conjunctivitis, diabetic retinopathy, Sjögren's syndrome, atopic disease, uveitis, allergic rhinitis, food allergies, allergic reactions, autoimmune diseases, drug hypersensitivity, mastocytosis, asthma, asbestosis, silicosis, chronic obstructive pulmonary disease, chronic granulomatous inflammation, cystic fibrosis, histiocytosis, sarcoidosis, glomerulonephritis, vasculitis, dermatitis, HIV-associated cachexia, cerebral malaria, ankylosing spondylitis, leprosy, COPD, pulmonary fibrosis, fibromyalgia, cancers such as esophageal cancer, gastroesophageal reflux disease, Barrett's esophagus, esophagus), aplastic anemia, graft-versus-host disease, sickle cell disease, CVID, hyper-IgM syndrome, IgA deficiency, transient hypogammaglobulinemia, X-linked agammaglobulinemia, chronic mucocutaneous candidiasis, DiGeorge syndrome, X-linked lymphoproliferative syndrome, ataxia-telangiectasia, chondro-hair dysplasia, combined immunodeficiency, hyper-IgE syndrome, MHC deficiency, severe combined immunodeficiency, Wiskott-Aldrich syndrome, Chediak-Higashi syndrome, chronic granulomatous disease, leukocyte adhesion deficiency, IFN-γ receptor deficiency, interleukin (IL)-12 deficiency, IL-12 receptor β1 deficiency, ZAP-70 deficiency, and angioedema.
[0063] The placenta-derived stem cells in the present invention are cells of fetal origin, have low immunogenicity, and have the ability to differentiate into three germ layer cells. Examples of placenta-derived stem cells include, but are not limited to, mesenchymal stem cells, hematopoietic stem cells, neural stem cells, placental pluripotent cells, and embryonic stem cells.
[0064] The cord blood-derived cells in the present invention are cells included in the cord blood, and examples thereof include hematopoietic stem cells, mononuclear cells, B cells, T cells, NK cells, platelets, and the like.
[0065] The peripheral blood mononuclear cells in the present invention are mononuclear cells separated from peripheral blood, and examples thereof include B cells, T cells, NK cells, monocytes, dendritic cells and the like.
[0066] Examples of bone marrow cells in the present invention include hematopoietic stem cells and mesenchymal stem cells.
[0067] (Ultrasound (Ultrasound))
[0068] In the present invention, "ultrasound (ultrasound)" refers to a sound wave having a frequency higher than the human audible range, and refers to a sound wave having a high frequency of 20kHz (kilohertz) or more. In the present invention, there is no particular limitation on ultrasonic wave (ultrasound), and its frequency is, for example, 20kHz (kilohertz) to 20MHz (megahertz), preferably 20kHz to 10MHz, more preferably 20kHz to 5MHz, further preferably 20kHz to 3MHz, particularly preferably 30kHz to 2MHz, more particularly preferably 40kHz to 1.5MHz, and most preferably 500kHz to 1.5MHz.
[0069] In the present invention, the intensity of ultrasonic waves (ultrasound) is not particularly limited, and is, for example, 0.1 mW / cm 2 Up to 200mW / cm 2 , preferably 0.6 mW / cm 2 Up to 100mW / cm 2 , more preferably 1mW / cm 2 Up to 75mW / cm 2 , and more preferably 10 mW / cm 2 Up to 50mW / cm 2 .
[0070] In the present invention, the ultrasonic duty ratio is not particularly limited, and is, for example, 1% to 95%, preferably 5% to 75%, more preferably 10% to 60%, and further preferably 20% to 50%.
[0071] In the present invention, the ultrasonic treatment time is appropriately adjusted according to the frequency, intensity or duty cycle, for example, 10 seconds to 1 hour, preferably 30 seconds to 30 minutes, more preferably 1 minute to 20 minutes, more preferably 1.5 minutes to 15 minutes, and particularly preferably 2 minutes to 10 minutes.
[0072] In the present invention, when the cells are mesenchymal stem cells, the conditions for ultrasonic treatment are preferably: a frequency of 20 kHz to 3 MHz, an intensity of 0.6 mW / cm 2 Up to 100mW / cm 2 , a duty cycle of 5% to 75%, and a treatment time of 1 minute to 20 minutes, more preferably: a frequency of 30kHz to 2MHz, an intensity of 1mW / cm2 Up to 75mW / cm 2 , the duty cycle is 10% to 60%, the treatment time is 1.5 minutes to 15 minutes, and further preferably: the frequency is 40kHz to 1.5MHz, the intensity is 10mW / cm 2 Up to 50mW / cm 2 , the duty cycle is 20% to 50%, and the treatment time is 2 minutes to 10 minutes.
[0073] The ultrasonic generator that can be used in the present invention is not particularly limited as long as it can generate ultrasonic waves, and examples thereof include METRON ACCUSONIC PLUS ULTRASOUND THERAPY UNIT (MODEL AP100, MetronMedical Australia Pty Ltd).
[0074] When the cells are subjected to ultrasonic treatment in the present invention, a culture container such as a flask or dish or tube containing a cell suspension may be provided in the ultrasonic device for treatment, or ultrasonic waves may be directly applied by inserting an ultrasonic source into the culture container or the cell suspension. That is, in the present invention, the ultrasonic treatment of the cells may be indirect irradiation via a culture container or the like in which the cells are cultured, or direct irradiation of the cells themselves or the cell suspension. In the present invention, from the viewpoint of the effect of the present invention, it is preferred that the culture container is provided in the ultrasonic device for treatment.
[0075] One embodiment of the method for preparing cells for treating a disease according to the present invention will be described in detail.
[0076] The cells are inoculated in a culture vessel and cultured, and after 0 to 4 days of culture, preferably after 1 to 2 days of culture, the culture vessel is arranged in an ultrasonic generator while the cells are still cultured, and ultrasonic treatment is performed from the bottom surface of the culture vessel. Frequency, intensity, duty cycle, and treatment time can be appropriately adjusted according to the number or purpose of the cell type, the cell, etc., and ultrasonic treatment is performed under the above-mentioned condition range. The state of the cell to be ultrasonically treated can be, for example, the state of cultured cells collected in a test tube or the state of frozen cells thawed as described above in a culture vessel.
[0077] The cells after ultrasonic treatment can be used for disease treatment as they are, or can be used for disease treatment after being cultured for a period of time. In addition, the cells after ultrasonic treatment can be cultured and then passaged once or more before being used for disease treatment.
[0078] As shown by the scratch test, the cells obtained by the method for preparing cells for treating diseases according to the present invention have a higher migration ability than normal cells, and also have a wound repair ability superior to normal cells. Therefore, according to the present invention, cells with high accumulation at the disease site can be provided, thereby further enhancing the therapeutic effect on inflammatory diseases or tumors, etc. In particular, when the cells obtained by the method for preparing cells for treating diseases according to the present invention are mesenchymal stem cells, the therapeutic effect can be further enhanced in the treatment of various diseases in which the above-mentioned mesenchymal stem cells can be used. The cells prepared by the method of the present invention are preferably used as drugs for treating diseases.
[0079] <Method for promoting cell migration ability>
[0080] The present invention also includes a method for promoting the migration ability of cells, wherein the method includes subjecting cells to ultrasonic treatment. According to the present invention, by subjecting cells to ultrasonic treatment under specific conditions, the migration ability of cells can be promoted and the accumulation of cells at the disease site can be increased. Therefore, the cells obtained by the method of the present invention can be preferably used to treat diseases such as inflammatory diseases or tumors. The specific details of the method for promoting the migration ability of cells according to the present invention are the same as those of the above-mentioned method for preparing cells for treating diseases according to the present invention, so for the specific description of the former, the description in the part of the method for preparing cells for treating diseases can be applied.
[0081] <Method for promoting cell proliferation ability>
[0082] The present invention also includes a method for promoting the proliferation ability of cells, the method comprising subjecting cells to ultrasonic treatment. According to the present invention, by subjecting cells to ultrasonic treatment under specific conditions, the proliferation ability of cells can be promoted and a large amount of such cells can be accumulated at the disease site. Therefore, the cells obtained by the method of the present invention can be preferably used to treat diseases such as inflammatory diseases or tumors. The specific details of the method for promoting the proliferation ability of cells according to the present invention are the same as those of the above-mentioned method for preparing cells for treating diseases according to the present invention, so for the specific description of the former, the description in the part of the method for preparing cells for treating diseases can be applied.
[0083] <Cells obtained by the method of the present invention>
[0084] The method of the present invention is the method for preparing the above-mentioned cell for treating disease, the method for promoting the migration ability of cell and the method for promoting the proliferation ability of cell, and the present invention also includes the cell obtained by these methods. The cell obtained by the method of the present invention is the cell treated with ultrasound by the method of the present invention, and the cell type and ultrasound conditions (frequency, intensity, duty cycle and processing time, etc.) are as described in the part of the method for preparing the cell for treating disease. Its specific examples include the cell treated with ultrasound with a frequency of 40 kHz to 1.5 MHz and the mesenchymal stem cell treated with ultrasound with a frequency of 40 kHz to 1.5 MHz. The cell obtained by the method of the present invention is preferably used as a medicine for the treatment of disease. The present invention also includes the invention of the pharmaceutical composition for the treatment of disease, which comprises the cell obtained by the method of the present invention.
[0085] As shown by the scratch test, compared with the usual cells, the cells obtained by the method of the present invention are cells with promoted migration ability and proliferation ability and increased wound repair ability due to the ultrasonic treatment under specific conditions, and it is unclear what changes have occurred in the cells by ultrasonic treatment to obtain such cells. At least as illustrated by the present invention, as shown by the scratch test, compared with the usual cells, the cells subjected to ultrasonic treatment under the above conditions are cells with promoted migration ability and proliferation ability and enhanced wound repair ability, and are preferably used as cells for treating diseases. It is believed that cells are affected by ultrasonic treatment in many ways. It is believed that the combination of various characteristic changes such as promoting any protein synthesis, inhibiting any protein synthesis, inactivation or activation of existing proteins, or the influence on cell membranes leads to the promotion of migration ability, promotion of proliferation ability, and the effect of enhancing wound repair ability as shown by the scratch test. It is believed that it is impossible or impractical to specify all such characteristic changes by further research or measurement, etc. Therefore, the cell of the present invention is specified by the method for preparing cells for treating diseases according to the present invention, the method for promoting the migration ability of cells, or the method for promoting the proliferation ability of cells.
[0086] The present invention also includes a culture supernatant of cells obtained by the method of the present invention. Specific examples thereof include a culture supernatant of cells treated with ultrasound at a frequency of 40 kHz to 1.5 MHz, and a culture supernatant of mesenchymal stem cells treated with ultrasound at a frequency of 40 kHz to 1.5 MHz. The culture supernatant of cells obtained by the method of the present invention is preferably used for therapeutic purposes for diseases, cosmetics or various purposes, etc.
[0087] Example
[0088] Hereinafter, the present invention will be described in detail with reference to Examples and Test Examples, but the present invention is not limited to these Examples and the like.
[0089] Experimental Example 1: Ultrasonic Treatment of Adipose-Derived Mesenchymal Stem Cells-1
[0090] The cells were plated at 6,000 cells / cm using a medium for mesenchymal stem cells (Growth Medium 2, PROMOCELL GmbH). 2 Adipose-derived mesenchymal stem cells (hereinafter referred to as "ADMSCs") were seeded in a 35 mm culture container. After seeding, only on the third day (one irradiation) or on the second and third days (two irradiations), the culture container in which the ADMSCs were cultured was set in an ultrasound device (manufactured by Opharmic) and ultrasonicated from the bottom surface of the culture container. The frequency was 40 kilohertz (KHz) and 1 megahertz (MHz), and the intensity was 30 mW / cm 2 . The duty cycle was 20%, and the treatment time was 2 minutes, 5 minutes, and 10 minutes. The control group was not treated with ultrasound (CNTL). The proliferation ability of the cells after ultrasound treatment was evaluated. Cell passage and cell counting were performed on the fourth day after the final ultrasound treatment. First, the culture supernatant of the cells was removed, the cells were washed with PBS, and TrpLE was added to separate the cells. After centrifugation, about 10 μL of cells resuspended in the culture medium were collected, and the cells were counted using trypan blue staining solution. After counting, the cells were inoculated in a fresh culture container.
[0091] Although a decrease in proliferation was observed under any condition at 40 kilohertz (KHz), Figure 1 ), but an increase in proliferation was observed at 1 MHz ( Figure 2 ).
[0092] Experimental Example 2: Ultrasonic Treatment of Adipose-Derived Mesenchymal Stem Cells-2
[0093] In the same manner as in Experimental Example 1, ADMSCs were cultured and subjected to ultrasonic treatment after 1 day and 2 days. The frequency was 1.5 MHz and the intensity was 30 mW / cm 2 , the duty cycle was 20%, and the treatment time was 2 minutes, 5 minutes, and 10 minutes. The negative control was not treated with ultrasound. The proliferation ability of the cells after ultrasound treatment was evaluated in the same manner as in Test Example 1. The results of counting the number of cells are shown in Figure 3 .
[0094] like Figure 3 As shown, no effect on proliferation capacity was observed at 1.5 MHz.
[0095] Experimental Example 3: Ultrasonic Treatment of Adipose-Derived Mesenchymal Stem Cells-3
[0096] In the same manner as in Experimental Example 1, ADMSCs were cultured and subjected to ultrasonic treatment after 1 day (one irradiation) or after 1 day and after 2 days (two irradiations). The frequency was 1 megahertz (MHz) and the intensity was 30 mW / cm 2 , the duty cycle was 50%, and the treatment time for the single irradiation group was 10 minutes, while the treatment time for the double irradiation group was 2 minutes and 5 minutes. The negative control was not treated with ultrasound. The proliferation ability of cells after ultrasound treatment was evaluated in the same manner as in Experimental Example 1. The cell counting results are shown in Figure 4 .
[0097] like Figure 4 As shown, an increase in proliferation capacity was observed in both irradiations.
[0098] Experimental Example 4: Ultrasonic Treatment of Adipose-Derived Mesenchymal Stem Cells-4
[0099] In the same manner as in Experimental Example 1, ADMSCs were cultured and subjected to ultrasonic treatment twice in total on the first and second days when the inoculation day was set to day 0. The frequency was 1.5 MHz and the intensity was 30 mW / cm 2 , the duty cycle was 50%, and the treatment time was 10 minutes. The negative control was not treated with ultrasound. The proliferation ability of the cells after ultrasound treatment (on the third day after inoculation) was evaluated in the same manner as in Test Example 1. The results of counting the number of cells are shown in Figure 5 .
[0100] like Figure 5 As shown, no effect on the proliferation ability was observed even at 1.5 MHz and a duty cycle of 50%.
[0101] Experimental Example 5: Scratch test on ADMSCs subjected to ultrasound treatment
[0102] In the same manner as in Experimental Example 1, ADMSCs were cultured and subjected to ultrasonic treatment twice in total on the first and second days when the inoculation date was set to day 0. The frequency was 1.5 MHz and the intensity was 30 mW / cm 2 , the duty cycle was 50%, and the treatment time was 5 minutes and 10 minutes. The medium for mesenchymal stem cells (PROMOCELL GmbH) was used at 15,000 cells / cm 2The ADMSCs subjected to ultrasound treatment were seeded in a culture vessel with a diameter of 35 mm. After confirming that the cells were in a confluent state, a 200 μL pipette tip was used to scrape the center of the culture vessel in which the ADMSCs were cultured in a straight line to create a gap. Thereafter, the cells were washed twice with PBS, 2 mL of GM2 medium (PROMOCELL GmbH) was added, and the cells were cultured at 37 ° C and a carbon dioxide concentration of 5%. At 0 hours, 4 hours, 9 hours, and 24 hours after the gap was created, the cells were observed under a microscope and images were acquired. After 9 hours, the width of the gap of each cell was measured. The results are shown in Figure 6 and Figure 7 .
[0103] like Figure 6 and Figure 7 As shown, ultrasound treatment enhanced the extent of wound repair as demonstrated by scratch assay.
[0104] Experimental Example 6: Migration ability test of ADMSCs subjected to ultrasound treatment
[0105] In the same manner as in Test Example 1, ADMSC was cultured, and the ADMSC subjected to ultrasonic treatment twice on the first day and the second day when the inoculation date was set to the 0th day was seeded in a Transwell culture container (Corning) of a 24-well plate at 3,000 cells per well using a culture medium for mesenchymal stem cells (PROMOCELL GmbH). After 24 hours, the cells were washed with PBS, and 4% paraformaldehyde was added to fix the cells that migrated to the lower surface of the Transwell. These cells were stained with DAPI. Cell counting was performed under a fluorescence microscope, and the average values of the results of the three measurements were compared. In addition, fluorescence micrographs were also taken. In the ultrasonic treatment, the frequency was 1.5 megahertz (MHz) and the intensity was 30mW / cm 2 , the duty cycle was 20% or 50%, and the treatment time was 2 minutes, 5 minutes, and 10 minutes. The results are shown in Figure 8 and Fig. 9 .
[0106] like Figure 8 and Fig. 9 As shown, under any irradiation condition, the number of cells migrating to the lower surface of the Transwell increased compared with the non-irradiated control, indicating that ultrasonic treatment enhanced the migration ability of cells.
[0107] Although data are not shown, an increase in the expression level of the migration ability-related gene by ultrasonic treatment was observed under any conditions, and a tendency to become higher was particularly observed at a frequency of 1.5 megahertz (MHz).
[0108] Experimental Example 8: Subculture of ADMSCs subjected to ultrasound treatment
[0109] The ADMSCs subjected to ultrasonic treatment in the same manner as in Experimental Example 1 were separated using trypsin, subcultured for one passage, and cultured in a medium for mesenchymal stem cells (PROMOCELL GmbH) to obtain subcultured cells. The frequency of the ultrasonic treatment was 1.5 MHz, and the intensity was 30 mW / cm 2 , the duty cycle is 50%, and the treatment time is 5 minutes.
[0110] Test Example 9: Migration ability test of subcultured cells
[0111] For the subcultured cells obtained in Test Example 8, a migration ability test was performed in the same manner as in Test Example 6. After 24 hours, the cells that migrated to the lower surface of the Transwell were counted, and the average values of the results of three measurements were compared. In addition, fluorescent micrographs were taken. The results are shown in Fig.10 and Fig.11 In addition, the ultrasound-untreated group was recorded as CNTL, and the ultrasound-treated group was recorded as US.
[0112] like Fig.10 and Fig.11 As shown, even for subcultured cells, sonication increased the number of cells that migrated to the lower surface of the Transwell.
[0113] Test Example 10: Scratch test of subcultured cells
[0114] For the subcultured cells obtained in Test Example 8, the center of the culture container in which ADMSCs were cultured was scraped in a straight line to create a gap in the same manner as in Test Example 5, and the cells were observed under a microscope at 0 hours, 4 hours, 9 hours, and 24 hours after the start of the culture, and images were acquired. In addition, after 9 hours, the width of the gap of each cell was measured. The results are shown in Fig.12 and Fig.13 In addition, the ultrasound-untreated group was recorded as CNTL, and the ultrasound-treated group was recorded as US.
[0115] Even for subcultured cells, ultrasound treatment enhanced the extent of wound repair as shown by the scratch assay ( Fig.12 and Fig.13 ).
[0116] Experimental Example 11: Freezing and culturing of ADMSCs subjected to ultrasonic treatment
[0117] The ADMSC subjected to ultrasonic treatment in the same manner as in Test Example 8 is separated using trypsin and centrifuged to obtain the precipitation of cells. Remove the supernatant, then add an appropriate amount of cell cryopreservation solution (Lonza Group AG), and suspend the cells. The gained cell suspension is distributed in a cryovial, then stored in a freezer at -80 ° C, then transferred to a gas phase higher than liquid nitrogen, and continue to store. The ultrasonically treated frozen cells are revived and cultivated in a culture medium (Promo Cell GmbH) for mesenchymal stem cells, to obtain ultrasonically treated frozen cultured cells.
[0118] Test Example 12: Ultrasonication-treated frozen cultured cells migration test
[0119] For the cryopreserved cultured cells obtained in Test Example 11, a migration ability test was performed in the same manner as in Test Example 6. That is, 24 hours after inoculation in the Transwell culture container, the cells that migrated to the lower surface of the Transwell were counted, and the average values of the results of three measurements were compared. The results are shown in Fig.14 and 15 .
[0120] In addition, the ultrasound-untreated group was recorded as CNTL, and the ultrasound-treated group was recorded as US.
[0121] Even for frozen cultured cells, sonication increased the number of cells that migrated to the lower surface of the Transwell compared to untreated frozen cultured cells.
[0122] Experimental Example 13: Scratch test of cryo-cultured cells treated with ultrasound
[0123] For the ultrasonically treated frozen cultured cells obtained in Test Example 11, the center of the culture container in which the cells were cultured was scraped along a straight line to generate a gap in the same manner as in Test Example 5, and the cells were observed under a microscope at 0 hours, 4 hours, 9 hours, and 24 hours after the start of the culture, and images were acquired. After 9 hours, the width of the gap of each cell was measured. The results are shown in Fig.16 and Fig.17 In addition, the ultrasound-untreated group was recorded as CNTL, and the ultrasound-treated group was recorded as US.
[0124] Even for frozen cultured cells, as shown by the scratch assay, ultrasound treatment accelerated the migration rate of cells after scratching and the rate of wound repair ( Fig.16 and Fig.17 ).
[0125] Industrial Applicability
[0126] According to the present invention, a novel method for promoting the migration ability of cells and cells having the migration ability promoted thereby can be provided. In addition, according to the present invention, a novel method for promoting the proliferation ability of cells and cells having the proliferation ability promoted thereby can be provided. Therefore, according to the present invention, cells having excellent migration ability and cells having promoted proliferation ability can be obtained, and therefore it is believed that a large number of cells can be accumulated in disease sites such as inflammatory tissues.
Claims
1. A method for preparing cells for treating a disease, the method comprising subjecting the cells to ultrasonic treatment.
2. The method for preparing cells for treating diseases according to claim 1, wherein the frequency of the ultrasonic treatment is 30 kHz to 2.0 MHz.
3. The method for preparing cells for treating a disease according to claim 1 or 2, wherein the cells are mesenchymal stem cells.
4. A method for promoting the migration ability of cells, the method comprising subjecting the cells to ultrasonic treatment. 5 . The method for promoting the migration ability of cells according to claim 4 , wherein the frequency of the ultrasonic treatment is 30 kHz to 2.0 MHz. The method for promoting the migration ability of cells according to claim 4 or 5, wherein the cells are mesenchymal stem cells.
7. A method for promoting cell proliferation, the method comprising subjecting the cells to ultrasonic treatment.
8. The method for promoting cell proliferation according to claim 7, wherein the frequency of the ultrasonic treatment is 30 kHz to 2.0 MHz. 9 . The method for promoting cell proliferation according to claim 7 or 8 , wherein the cells are mesenchymal stem cells.
10. Cells treated with ultrasound at a frequency of 30 kHz to 2.0 MHz.
11. Mesenchymal stem cells treated with ultrasound at a frequency of 30 kHz to 2.0 MHz.
